Apellis Board Unanimously Recommends Biogen's $41.00 Cash + CVR Tender Offer, Citing Significant Premium

summarizeSummary

Apellis Pharmaceuticals' Board of Directors has unanimously recommended shareholders accept Biogen's tender offer of $41.00 per share in cash plus a Contingent Value Right (CVR) for up to an additional $4.00, representing a substantial premium and providing immediate liquidity.

check_boxKey Events

• Board Unanimously Recommends Tender Offer

  Apellis's Board of Directors unanimously recommends that stockholders accept Biogen's tender offer and tender their shares.

• Acquisition Terms Detailed

  Biogen is offering $41.00 per share in cash upfront, plus one Contingent Value Right (CVR) per share, potentially worth up to an additional $4.00 based on SYFOVRE sales milestones.

• Significant Premium Achieved

  The offer represents a 140% premium over the closing price on March 30, 2026, and a 35% premium to the 52-week high price, demonstrating a favorable valuation for shareholders.

• Extensive Negotiation and Market Check

  The board engaged in a thorough process, including rejecting multiple lower offers from Biogen and conducting a targeted market check with seven other potential acquirers, none of whom submitted a proposal.

auto_awesomeAnalysis

This SC 14D9 filing provides the full details and rationale behind Apellis's Board of Directors' unanimous recommendation to accept Biogen's tender offer. The offer, valued at $41.00 per share in cash plus a CVR for up to $4.00, represents a significant premium over recent trading prices, including a 140% premium to the closing price on March 30, 2026, and a 35% premium to the 52-week high. The board's decision follows a robust negotiation process, including multiple rejected offers and a market check with other potential acquirers, indicating a diligent pursuit of maximum shareholder value. The inclusion of CVRs allows shareholders to participate in the future commercial success of SYFOVRE, mitigating the loss of future growth potential. The deal structure as a tender offer, supported by key insiders holding 14% of shares, and the completion of HSR filings, suggest a high likelihood of timely consummation. This transaction fundamentally alters the investment thesis for Apellis shareholders, offering immediate, certain value at a favorable price.